OMGA Omega Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: OMGA

Price (delayed)

$2.76

Market cap

$152.23M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.8

Enterprise value

$211.87M

Highlights
The company's gross profit rose by 49% YoY and by 9% QoQ
The revenue has increased by 49% year-on-year and by 9% since the previous quarter
Omega Therapeutics's quick ratio has decreased by 48% YoY and by 11% from the previous quarter
The equity has declined by 45% year-on-year and by 24% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OMER

Key stats

What are the main financial stats of OMGA
Market
Shares outstanding
55.15M
Market cap
$152.23M
Enterprise value
$211.87M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.62
Price to sales (P/S)
48.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
68.48
Earnings
Revenue
$3.09M
EBIT
-$97.43M
EBITDA
-$90.66M
Free cash flow
-$93.73M
Per share
EPS
-$1.8
Free cash flow per share
-$1.74
Book value per share
$1.05
Revenue per share
$0.06
TBVPS
$3.78
Balance sheet
Total assets
$204.37M
Total liabilities
$146.35M
Debt
$128.43M
Equity
$58.02M
Working capital
$63.08M
Liquidity
Debt to equity
2.21
Current ratio
3.35
Quick ratio
2.98
Net debt/EBITDA
-0.66
Margins
EBITDA margin
-2,930.1%
Gross margin
100%
Net margin
-3,148.9%
Operating margin
-3,240.5%
Efficiency
Return on assets
-48.3%
Return on equity
-110.4%
Return on invested capital
-52.6%
Return on capital employed
-54.9%
Return on sales
-3,148.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OMGA stock price

How has the Omega Therapeutics stock price performed over time
Intraday
11.29%
1 week
17.45%
1 month
-8.31%
1 year
-67.03%
YTD
-8.31%
QTD
-24.38%

Financial performance

How have Omega Therapeutics's revenue and profit performed over time
Revenue
$3.09M
Gross profit
$3.09M
Operating income
-$100.26M
Net income
-$97.43M
Gross margin
100%
Net margin
-3,148.9%
The company's gross profit rose by 49% YoY and by 9% QoQ
The revenue has increased by 49% year-on-year and by 9% since the previous quarter
The net margin has grown by 36% year-on-year and by 17% since the previous quarter
The company's operating margin rose by 35% YoY and by 17% QoQ

Growth

What is Omega Therapeutics's growth rate over time

Valuation

What is Omega Therapeutics stock price valuation
P/E
N/A
P/B
2.62
P/S
48.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
68.48
The EPS has grown by 16% YoY and by 13% from the previous quarter
The equity has declined by 45% year-on-year and by 24% since the previous quarter
The stock's price to book (P/B) is 4.8% more than its last 4 quarters average of 2.5
The revenue has increased by 49% year-on-year and by 9% since the previous quarter
The price to sales (P/S) is 44% less than the last 4 quarters average of 86.0

Efficiency

How efficient is Omega Therapeutics business performance
OMGA's ROE has plunged by 55% YoY and by 2.4% from the previous quarter
The ROIC has grown by 47% YoY and by 31% from the previous quarter
The ROS has grown by 36% YoY and by 19% from the previous quarter
OMGA's return on assets is up by 16% since the previous quarter and by 15% year-on-year

Dividends

What is OMGA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OMGA.

Financial health

How did Omega Therapeutics financials performed over time
The total assets is 40% greater than the total liabilities
Omega Therapeutics's quick ratio has decreased by 48% YoY and by 11% from the previous quarter
Omega Therapeutics's current ratio has decreased by 46% YoY and by 12% from the previous quarter
The debt is 121% greater than the equity
The equity has declined by 45% year-on-year and by 24% since the previous quarter
OMGA's debt to equity is up by 28% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.